Dr. Makower is the Founder & Chief Executive Officer of ExploraMed Development, LLC, a medical device incubator based in California. He is also a Venture Partner with New Enterprise Associates. Dr. Makower serves as a Consulting Associate Professor of Medicine at Stanford University Medical School and co-founded Stanford’s Biodesign Innovation Program. Dr. Makower has founded several other companies which have achieved successful M&A transactions including Acclarent, a company focused on developing novel therapies in ENT, which was sold to J&J in 2010, TransVascular, Inc., a company focused on the development of a completely catheter-based coronary bypass technology, which was acquired by Medtronic, Inc. in 2003, and EndoMatrix, Inc., a company focused on the development of a novel therapy for incontinence and GI Reflux, which was acquired by C.R. Bard in 1997. Up until 1995, Dr. Makower was Founder and Manager of Pfizer’s Strategic Innovation Group, a group chartered to create new medical device technologies and businesses for Pfizer’s medical device businesses. Dr. Makower also serves on the Board of Directors for Neotract, Inc., Intrinsic Therapeutics, Inc., ExploraMed III, Inc. and Vibrynt, Inc. He holds over five dozen patents for various medical devices in the fields of Orthopedics, ENT, Cardiology, General Surgery, Drug Delivery and Urology. Dr. Makower holds an MBA from Columbia University, an MD from the New York University School of Medicine, and a BS in Mechanical Engineering from the Massachusetts Institute of Technology.
In February 2008 Kevin Sidow began his role as President and Chief Executive Officer for Moximed Inc. Prior to his current role, he was President and CEO for St. Francis Medical Technologies, Inc. Founded in 1997, St. Francis Medical Technologies was a privately held, venture funded company focused on developing innovative treatments for patients suffering from degenerative spinal disorders. In January 2007, St. Francis Medical Technologies, Inc. was sold for $725 million to Kyphon Inc. Previously, Kevin was the Worldwide President of DePuy Inc., where he oversaw the global orthopedic, spine, trauma, and sports medicine businesses with annual revenue responsibility of over $3 billion. Kevin holds a BS in Accounting from West Virginia University.
Mr. Drant is a General Partner of New Enterprise Associates (NEA). He specializes in healthcare investments in the medical device, specialty pharma and healthcare services sectors. Prior to joining NEA, Mr. Drant was with the Health Care Investment Banking Group of Alex. Brown & Sons in San Francisco. Mr. Drant holds a BA from Stanford University.
Mr. Franken joined Gilde Healthcare Partners in 2001 and became a Partner in 2007. He is focusing his investment activities on medical devices, diagnostics and (bio)pharmaceuticals. He led the investments in Conatus Pharmaceuticals, Inc., FlowCardia, Inc. (acquired by C. R. Bard, Inc. (NYSE: BCR)), Moximed Inc. and MTM Laboratories AG and was involved in numerous investments and divestments including Ablynx (IPO on Euronext), Agendia, AMT (IPO on Euronext), BG Medicine (IPO on NASDAQ), IDEA, Neuro3D (acquired by Evotec) and Pieris. Mr Franken represents Gilde on the boards of MTM Laboratories and Moximed Inc. He served as a board member for FlowCardia until its acquisition by C. R. Bard, Inc. and observed on the boards of Agendia and AMT until its IPO on Euronext. He received his masters degree in Biopharmaceutical Sciences from Leiden University, the Netherlands. He is a Dutch national.
Christopher Shen, M.D. is a Managing Director and head of U.S. healthcare investing at Vertex Management. Dr. Shen specializes in investments in biopharmaceutical and medical device companies. Previously, Dr. Shen worked at Essex Woodlands Health Ventures, a healthcare-focused venture capital and private equity firm. Prior to joining EWHV, he worked at New Enterprise Associates, one of the largest, diversified venture capital firms. Previously, Dr. Shen held the position of Senior Design Engineer at Guidant Corporation’s Neurovascular Venture, an internal start-up, where he invented and commercialized a minimally-invasive therapy for the treatment of acute ischemic stroke. Dr. Shen also worked in Japan as a Design Engineer for Pfizer, Inc.’s Strategic Innovation Group, an internal medical technology incubator.
Dr. Shen is the U.S. Executive Director of the Singapore Stanford Biodesign Program and a Consulting Associate Professor of Medicine at Stanford University, focusing on medical technology innovation. He has nine patents issued and several pending in the fields of interventional neuroradiology and interventional cardiology.
Dr. Shen received his Doctor of Medicine from the Stanford School of Medicine, his Master of Business Administration from Stanford Graduate School of Business, and a Master of Biomechanical Engineering from the Stanford School of Engineering. He received his Bachelor of Science in Biological Sciences from Stanford University.
Mr. Plain joined Morgenthaler Ventures in 2007 after more than 25 years in the life science industry, including co-founding eight medical device start-ups and directing the exits of four companies with a combined value well in excess of $1 billion. Mr. Plain is also the Vice Chairman of The Foundry, a medical device incubator based in Redwood City, California, where he co-founded Ardian, Cabochon Aesthetics, Cierra, Emphasys Medical, ForSight Labs, Satiety, Transcend and Xtent. He is a board member of Access Closure, Acclarent, and Moximed Inc. He served as President and CEO at Perclose, Inc. from 1993 to 2000, during which time he led the company to $100 million in sales and managed the company’s successful IPO and acquisition in 1999 by Abbott Laboratories for $650 million. He was Chairman of Embolic Protection, where he helped negotiate the acquisition of the company in 2001 by Boston Scientific for $200 million. He also served as a Director at TransVascular, Inc. until Medtronic acquired the company in 2003 for an undisclosed amount. Previously, Mr. Plain worked at Eli Lilly for 12 years in various management positions.
Mr. Anderson co-founded Valleylab, Inc. in 1969. He served as CEO and Chairman until January 1986, when he relinquished his role as CEO and continued as Chairman until retiring in May 1996. The company, which focuses on electrosurgical and ultrasonic systems, was acquired by Pfizer, Inc., in 1983. Mr. Anderson was named the first Boulder Entrepreneur of the Year in 1985. He has been a board member of more than 30 companies, and is currently a director of eight medically-related companies. In 1999, he received the “Pioneer in Endoscopy” award from the Society of American Gastrointestinal Surgeons, for his early work in “keyhole” surgery. He received the Outstanding Achievement Award from the University of Minnesota in June 1992. Mr. Anderson holds a bachelor’s degree in Electrical Engineering from the University of Minnesota.
Mr. Croce comes to Moximed® Inc. after a 36-year career at Johnson & Johnson where he held a series of senior positions, culminating with 12 years as Company Group Chairman. He has been a Venture Partner with New Enterprise Associates (NEA) since February 2005. Previously, he was Worldwide Franchise Chairman of Cordis, a Johnson & Johnson company. Prior to that, he was Worldwide Franchise Chairman for Ethicon Endo-Surgery. Mr. Croce began his career with Johnson & Johnson in 1968 as a Sales Representative for Ortho Pharmaceuticals, where he was later named Vice President of Marketing. In 1985, Mr. Croce moved to McNeil Pharmaceutical as Vice President of Business Development and later transferred to Ethicon, Inc. as Group Vice President, where he remained until he was named President in 1990. In 1992 he was promoted to Worldwide President, Ethicon Endo-Surgery. Mr. Croce is a graduate of Central Missouri State University, where he earned undergraduate and graduate degrees.